Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial.
Gayed J, Diya O, Lowry FS, Xu X, Bangad V, Mensa F, Zou J, Xie X, Hu Y, Lu C, Cutler M, Belanger T, Cooper D, Koury K, Anderson AS, Türeci Ö, Şahin U, Swanson KA, Modjarrad K, Gurtman A, Kitchin N; C4591054 Study Group.
Gayed J, et al. Among authors: anderson as.
Vaccines (Basel). 2024 Jan 24;12(2):118. doi: 10.3390/vaccines12020118.
Vaccines (Basel). 2024.
PMID: 38400102
Free PMC article.